On June 2, 2025, the FDA granted Breakthrough Device status to the BiVACOR Total Artificial Heart (TAH)—a next-generation fully implantable heart replacement system. What sets BiVACOR apart is its magnetically levitated pump, which allows for precise, continuous blood flow without the need for valves or diaphragms. The compact design is intended to serve as a…